<DOC>
	<DOCNO>NCT02049671</DOCNO>
	<brief_summary>Large population study hypopituitary adult ( patient pituitary gland failure ) conventional hormone replacement , growth hormone , approximate two fold increase death rate ( mortality ) . The vast majority excess mortality relate vascular disease . While possible overreplacement steroid , underreplacement thyroid hormone sex hormone deficiency contribute , increase data support role GH cause excess vascular risk . Although number surrogate vascular risk describe patient GH deficiency ( GHD ) , translate mechanistically atherothrombotic ( blockage artery ) disease fully elucidate . This propose study analyse traditional ( body composition , serum lipid , handle sugar ) complex marker ( inflammation , procoagulation , fibrinolysis ) vascular risk/disease . In addition study examine 24hr blood pressure , arterial wall thickness , clot structure function , well platelet action . Measurements perform baseline reassess patient stable dose GH replacement least three month . The result study characterise risk factor vascular disease , take step elucidate change translate mechanistically vascular damage .</brief_summary>
	<brief_title>Elucidation Effects Growth Hormone ( GH ) Deficiency GH Replacement Clot Platelet</brief_title>
	<detailed_description />
	<mesh_term>Hormones</mesh_term>
	<criteria>Able give write consent Adults confirm GHD ( Insulin stimulation test &lt; 3ug/L ) Other hormone replacement therapy stable least three month active malignancy acute vascular event within three month study therapy hormone replacement serum creatinine &gt; 120 micromol/l abnormal LFTs ( ALT &gt; 3 fold upper limit normal )</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>